Vellanki Avanish 4
4 · Rain Therapeutics Inc. · Filed Apr 27, 2021
Insider Transaction Report
Form 4
Vellanki Avanish
DirectorPresident and CEO
Transactions
- Conversion
Common Stock
2021-04-27+11,212→ 2,372,541 total - Conversion
Series A Preferred Stock
2021-04-27−12,108→ 0 total→ Common Stock (11,212 underlying)
Holdings
- 138,901(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date.